Artal Group S.A. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001053906

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedConsumer TiltHigh Turnover how tags are computed

Q2 2026 · 2 positions · Total reported value $931.12M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 1 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Artal Group S.A. disclosed 2 equity positions with a combined reported value of $931.12M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Consumer Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were CAVA ($510.75M), LXRX ($420.37M). By sector, the heaviest allocations are Consumer Discretionary 54.9%, Health Care 45.1%. Versus the prior quarter, allocation shifted toward Health Care (+21.3pp) and away from Consumer Discretionary (-21.3pp).

Versus the prior quarter, Artal Group S.A. opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Artal Group S.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-15 Sell CAVA GROUP, INC. 3,000,000 $90.30 SEC filing
2026-04-30 Opt exercise LEXICON PHARMACEUTICALS, INC. 20,421,735 — SEC filing

All insider transactions →

Fund Profile

Artal Group S.A. is an SEC-registered 13F filer. As of Q2 2026 it reported 2 US equity positions with a combined value of $931.12M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 2 positions · $931.12M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: CAVA (CAVA GROUP INC) at 54.9%
  • Average position size: $465.56M

Sector Tilt

  • Consumer Discretionary 54.9%
  • Health Care 45.1%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 added, 1 reduced

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Artal Group S.A. fund appears to be adjusting its holdings, with a significant shift towards Lexicon Pharmaceuticals Inc. This may suggest a shift in focus from consumer discretionary to health care, possibly reflecting a belief in the long-term prospects of the health care sector. 2. Key Moves: - Reduced CAVA: The fund significantly reduced its position in CAVA Group Inc., selling off 31.6% of its shares in the quarter. This suggests a cautious stance or a reevaluation of the consumer discretionary sector. - Added LXRX: Conversely, the fund increased its position in Lexicon Pharmaceuticals Inc. by 13.2%, indicating a strong commitment to the health care sector. 3. Portfolio Structure: - Active Management: The fund is actively managing its portfolio, evidenced by the significant changes in holdings. - Sector Bias: The shift from consumer discretionary to health care suggests a sector bias towards the latter, which may indicate a belief in the growth potential or stability of the health care sector. - Risk Appetite: The addition of a significant stake in a single company (Lexicon Pharmaceuticals) could suggest a higher risk appetite, though the overall reduction in CAVA might counterbalance this. 4. Per-Holding One-Liner: - CAVA: CAVA Group Inc. is a fast-casual restaurant company. (Unverified) - LXRX: Lexicon Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines. (Unverified) 5. One-Sentence Style Summary: The Artal Group S.A. fund shifted its focus from consumer discretionary to health care in Q2 2026, reducing its exposure to CAVA and increasing its stake in Lexicon Pharmaceuticals, possibly reflecting a belief in the health care sector's long-term potential.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 45.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.51M $510.75M 54.85%
54.85%
Reduce
2 175.16M $420.37M 45.15%
45.15%
Add

FAQ

What did Artal Group S.A. buy in 2026-Q2?

In its 2026-Q2 13F filing, Artal Group S.A. reported 2 equity positions worth $931.12M in aggregate; its largest disclosed positions were CAVA ($510.75M), LXRX ($420.37M).

How large is Artal Group S.A.'s portfolio?

Artal Group S.A. reported $931.12M of long equity holdings across 2 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Artal Group S.A.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Consumer Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/artal/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →